Patents by Inventor Yoshiko Hashii

Yoshiko Hashii has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cancer therapy utilizing combination of oral tumor vaccine and immunosuppression inhibitor
    Patent number: 11666646
    Abstract: It is an object to provide a combination therapy effective in cancer immunotherapy. The object is achieved by providing an anti-tumor agent, including a transformed Bifidobacterium containing DNA encoding a WT1 protein and DNA encoding a GNB/LNB substrate-binding membrane protein derived from a Bifidobacterium, the transformed Bifidobacterium being designed to display the WT1 protein as an antigen on a surface of the transformed Bifidobacterium, the anti-tumor agent being for use in combination with an immunosuppression inhibitor. The transformed Bifidobacterium can be used as an oral tumor vaccine.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: June 6, 2023
    Assignees: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, OSAKA UNIVERSITY
    Inventors: Toshiro Shirakawa, Yoshiko Hashii
  • Oral cancer vaccine
    Patent number: 10695385
    Abstract: A cancer vaccine that can be orally administered can be provided through the use of a transformed Bifidobacterium capable of expressing and displaying a WT1 protein. The WT1 protein expressed and displayed by the transformed Bifidobacterium is a protein covering most of a WT1 protein unlike a WT1 peptide vaccine restricted to a certain HLA. A cancer vaccine using the transformed Bifidobacterium as an active ingredient is applicable to patients of various HLA types.
    Type: Grant
    Filed: May 30, 2016
    Date of Patent: June 30, 2020
    Assignees: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, OSAKA UNIVERSITY
    Inventors: Toshiro Shirakawa, Takane Katayama, Yoshiko Hashii, Keiichi Ozono
  • Cancer Therapy Utilizing Combination Of Oral Tumor Vaccine And Immunosuppression Inhibitor
    Publication number: 20190351038
    Abstract: It is an object to provide a combination therapy effective in cancer immunotherapy. The object is achieved by providing an anti-tumor agent, including a transformed Bifidobacterium containing DNA encoding a WT1 protein and DNA encoding a GNB/LNB substrate-binding membrane protein derived from a Bifidobacterium, the transformed Bifidobacterium being designed to display the WT1 protein as an antigen on a surface of the transformed Bifidobacterium, the anti-tumor agent being for use in combination with an immunosuppression inhibitor. The transformed Bifidobacterium can be used as an oral tumor vaccine.
    Type: Application
    Filed: December 8, 2017
    Publication date: November 21, 2019
    Applicants: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, OSAKA UNIVERSITY
    Inventors: Toshiro SHIRAKAWA, Yoshiko HASHII
  • Oral Cancer Vaccine
    Publication number: 20180169156
    Abstract: A cancer vaccine that can be orally administered can be provided through the use of a transformed Bifidobacterium capable of expressing and displaying a WT1 protein. The WT1 protein expressed and displayed by the transformed Bifidobacterium is a protein covering most of a WT1 protein unlike a WT1 peptide vaccine restricted to a certain HLA. A cancer vaccine using the transformed Bifidobacterium as an active ingredient is applicable to patients of various HLA types.
    Type: Application
    Filed: May 30, 2016
    Publication date: June 21, 2018
    Inventors: Toshiro Shirakawa, Takane Katayama, Yoshiko Hashii, Keiichi Ozono